

Genetic validation of a new means of protecting men against cardiovascular disease

March 10 2022




Figure 1. Forest plots showing the SNP-specific and overall Mendelian randomization estimates for associations of genetically mimicking NK3R antagonists (based on rs116646027 and rs1351623, TACR3) with ischemic heart disease in men and the negative control outcome (ischemic heart disease in women) and the positive control outcomes in men (relative age voice broke, hypertension, prostate cancer and number of children fathered in men) per standard deviation lower testosterone in men from the UK Biobank and the PRACTICAL consortium (prostate cancer). Credit: *eBioMedicine* (2022). DOI: 10.1016/j.ebiom.2022.103901

Men have higher rates of cardiovascular disease and cancer than women,

which contributes to a substantially shorter life expectancy for men than for women—currently a difference of about five years in the United States.

Few public health interventions have been specifically designed to address this inequity. Recent research suggests sex hormones, particularly testosterone may play a role. One of the most commonly used drugs to prevent cardiovascular disease, statins, reduces testosterone and partially operates by that mechanism in men.

In a [previous study](#), published in *The Lancet*, CUNY SPH Professor Mary Schooling suggested that an existing drug (neurokinin 3 receptor (NK3R) antagonists) could also be used to prevent [cardiovascular disease](#) in men. NK3R antagonists are currently being investigated as a potential treatment for [menopausal symptoms](#) in women.

In a new study in one of *The Lancet* family journals, *EBioMedicine*, Professor Schooling shows that NK3R antagonists do indeed reduce the risk of ischemic heart disease in men specifically. The study used a technique called mendelian randomization, which made it possible to assess likely drug effects indirectly by taking advantage of genetic differences that mimic the effects of a [drug](#). An exploratory analysis suggested that NK3R antagonists might also protect men against [prostate cancer](#).

"These are translationally important findings that represent a practical new avenue for protecting men against the leading cause of death," Professor Schooling says.

More information: C.M. Schooling, Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men – A one-sample Mendelian randomization study, *eBioMedicine* (2022). [DOI: 10.1016/j.ebiom.2022.103901](https://doi.org/10.1016/j.ebiom.2022.103901)

Provided by The City University of New York

Citation: Genetic validation of a new means of protecting men against cardiovascular disease (2022, March 10) retrieved 3 May 2024 from <https://medicalxpress.com/news/2022-03-genetic-validation-men-cardiovascular-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.